1.Clinical observation on trimetazidine in treatment of chronic heart failure
Chinese Journal of Primary Medicine and Pharmacy 2011;18(23):3203-3204
Objective To explore the clinical effect of chlorpromazine(TMZ)in treatment of chronic heart failure(CHF).Methods 70 patients with CHF were randomly divided into control group and treatment group 35 cases in each gronp,control group was given conventional treatment,treatment group on the basis of additional application TMZ,20mg/times,3 times/d.8 weeks after the observation and comparison of two groups of cardiac function in improving the situation.Results Treatment group before the treatment of LVEF(38.0 ± 2.4)% After treatment,LVEF(48.0 ±2.3)% ;control group before treatment LVEF(38.2 ±2.2)% after treatment,LVEF(42.0 t2.5)% ;Twosets of treatment LVEFdifference statistically significant(t =6.9419,2.8482,allP < 0.05); Treatment group compared with control groups after treatment improve even more obvious(t =4.3147,P <0.05)o Control groups and then hospitalized 10 cases(28.5%),the treatment group hospitalization 3 cases(8.5%),both groups rate difference statistically significant(x2 =4.629,P <0.05).Both groups were no deaths,no serious adverse effects.Conclusion General against heart failure therapy on the basis of the combined with TMZ could significantly improve the cardiac function of patients with chronic heart failure,reducing hospitalization rates.
2.Clinical observation of tolterodine combined with flupentixol melitracen in the treatment of patients with overactive bladder
Youming TUO ; Shunli TANG ; Xiang CHEN
Chinese Journal of Primary Medicine and Pharmacy 2014;21(2):202-204
Objective To investigate the clinical efficacy and safety of tolterodine combined with flupentixol melitracen in the treatment of women with overactive bladder (OAB).Methods 84 female patients with OAB were chosen and randomly divided into the observation group and the control group.42 cases in observation group were treated with tolterodine combined with flupentixol melitracen.42 cases in control group were only treated with tolterodine.The clinical efficacy was recorded and compared after treatment for 4 weeks.Results The total effective rate of the observation group was higher than the control group (95.24% vs 76.19%,x2 =6.291,P < 0.05).The 24h frequency of urination,the average 24h number of incontinence episodes,initial urinate capacity and maximum bladder pressure capacity had statistically significant differences between the two groups (all P < 0.05).Conclusion Tolterodine combined with flupentixol melitracen in the treatment of women with OAB has advantages of short course of treatment,excellent efficacy,and few side effects.
3.The efficacy and safety of liver decanoic sulfonic sodium in the treatment of elderly patients with acute coronary syndrome
Xiang CHEN ; Youming TUO ; Shaohua CHEN ; Dali SU ; Pin Yü ; Yixin LI
Chinese Journal of Primary Medicine and Pharmacy 2013;20(5):673-675
Objective To observe the efficacy and safety of liver decanoic sulfonic sodium in the treatment of elderly patients with acute coronary syndrome (ACS).Methods84 ACS patients over 70 years were randomly divided into the treatment and control groups.Two groups were treated on the basis of general,treatment 40 cases of liver of dibutyl sebacate with sodium sulfonated added 2.5 mg subcutaneous injection parumbilical,day 1,course 8 d ; control group 44 cases combined with low molecular weight heparin calcium 0.4 ml,2 times/day 1 time every 12 hours,according to body weight adjusted dose,Parumbilical shot in course of 8 days,observing the clinical effect of two groups during the treatment,as well as 4 weeks and bleeding during the treatment the incidence of cardiovascular events.Results The clinical effects of treatment and control groups was no significant difference (95% and 91%,P >0.05) ; None of the two sets of death,myocardial infarction and recurrent malignant ventricular arrhythmia; none of the two sets of bleeding occurs,treatment of minor bleeding rates were significantly lower than those of control groups (7.5% and 25%,P < 0.05).Conclusion The study of dibutyl sebacate with sodium heparin and low molecular weight heparin calcium in the treatment of ACS are valid,but the former which significantly reduce the incidence of minor bleeding.Liver decanoic sulfonic sodium for acute coronary syndrome ACS)anticoagulation can not only effectively reduce cardiovascular events,but also significantly reduce bleeding risk,regardless of the patient's age,gender,renal function and risk stratification,especially for bleeding in high risk elderly patients with safe and clinical promotion.